TCM
ADPT icon

Towercrest Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Towercrest Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-11,000
Closed -$340K – 80
2019
Q3 		$340K Buy
+11,000
New +$449K 0.09% 55

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Towercrest Capital Management's ADPT Position: Q4 2019 in Review

Towercrest Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q4 2019, closing a stake of 11,000 shares — an estimated $340K sold.

Towercrest Capital Management first reported a position in ADPT in Q3 2019 and held it in 1 quarter. The position peaked at $340K in Q3 2019. 133 funds tracked by Wall St. Rank hold ADPT as of Q4 2019.

  • Towercrest Capital Management reported no remaining Adaptive Biotechnologies position as of Q4 2019 after selling out during the quarter.
  • Towercrest Capital Management sold 11,000 Adaptive Biotechnologies shares in Q4 2019, an estimated $340K.
  • Towercrest Capital Management first reported a position in Adaptive Biotechnologies in Q3 2019 and held it in 1 quarter.
  • Towercrest Capital Management's Adaptive Biotechnologies position peaked at $340K in Q3 2019.
  • 133 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2019.

Based on Towercrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.